Skip to main content

Table 3 Comparison of subjects with and without colistin-resistant E. coli or K. pneumoniae colonization at study enrollment

From: Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Variables Colonization at enrollment
(n = 24)
No colonization at enrollment
(n = 115)
p-value
Female gender 13 (54.2%) 57 (49.6%) 0.68
Age (yrs), mean ± SD 64.3 ± 18.8 67.8 ± 15.2 0.33
ICU admission, n (%) 9 (37.5%) 39 (33.9%) 0.77
Previous hospitalization, n (%) 15 (62.5%) 58 (50.4%) 0.28
Duration from hospital admission to enrollment (days), median (range) 19.5 (4–106) 15 (1–86) 0.10
Duration from enrollment to first sample collection (days), median (range) 1.5 (1–4) 1 (1–5) 0.48
APACHE II score at study enrollment, mean ± SD 20.6 ± 7.2 21.9 ± 7.4 0.65
Mechanical ventilation, n (%) 20 (83.3%) 97 (84.3%) 1.0
Indwelling central venous catheter, n (%) 17 (70.8%) 68 (59.1%) 0.29
Surgery, n (%) 19 (79.2%) 65 (56.5%) 0.04
Chronic intermittent hemodialysis, n (%) 4 (16.7%) 14 (12.2%) 0.74
Colistin use within 3 months prior to study enrollment, n (%) 4 (16.7%) 11 (9.6%) 0.47
Antibiotic use for the current hospitalization prior to study enrollment, n (%)
 Carbapenems 20 (83.3%) 92 (80.0%) 0.79
 Cephalosporins 9 (37.5%) 47 (40.9%) 0.76
 Beta-lactam/beta-lactamase inhibitors 16 (66.7%) 59 (51.3%) 0.17
 Fluoroquinolones 13 (54.2%) 26 (22.6%) 0.002
 Vancomycin 13 (54.2%) 30 (26.1%) 0.007
 Aminoglycosides 3 (12.5%) 3 (2.6%) 0.06
 Colistin 3 (13.6%) 6 (5.5%) 0.36
Length of hospital stay (days), median (range) 49.5 (13–138) 36 (6–246) 0.17
All-cause mortality at hospital discharge, n (%) 16 (66.7%) 54 (47.0%) 0.08